Efficacy of Expanded Newborn Screening for Metabolic Diseases
Author Information
Author(s): Lindner Martin, Gramer Gwendolyn, Haege Gisela, Fang-Hoffmann Junmin, Schwab Karl O, Tacke Uta, Trefz Friedrich K, Mengel Eugen, Wendel Udo, Leichsenring Michael, Burgard Peter, Hoffmann Georg F
Primary Institution: Centre for Paediatric and Adolescent Medicine, University Heidelberg
Hypothesis
How effective is expanded newborn screening for metabolic diseases over a 10-year period?
Conclusion
The study found that physical and cognitive outcomes for patients diagnosed presymptomatically with metabolic disorders are comparable to those of patients with phenylketonuria, the gold standard for newborn screening.
Supporting Evidence
- The study analyzed data from over a million newborns screened for metabolic disorders.
- It found that early diagnosis and treatment can lead to better health outcomes.
- Patients with medium-chain acyl-CoA dehydrogenase deficiency had particularly good outcomes.
Takeaway
This study shows that testing newborns for certain metabolic diseases can help catch problems early, which is important for their health and development.
Methodology
A prospective observational study analyzed 373 confirmed cases of metabolic disorders from 1,084,195 screened neonates.
Potential Biases
Potential biases may arise from the observational nature of the study and the specific population sampled.
Limitations
The study is limited to a single center and may not represent outcomes in other regions or populations.
Participant Demographics
The study included neonates screened in South-West Germany between 1999 and 2009.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI [0.88; 7.40]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website